Fig. 2

ANXA2 is the specific protein that interacts with CTGF. A Base peak chromatography from LC-MS/MS analysis of the proteins separated by SDS-PAGE gel electrophoresis after Co-IP using anti-CTGF antibody with FLSs lysates. IgG was used as a control. B The amino acid coverage of the identified ANXA2 sequence is shown with the appraisal sequence in yellow. C Co-IP using anti-ANXA2 and anti-CTGF antibodies with FLS lysates. D Immunofluorescence of CTGF and ANXA2 was performed in FLSs with a magnification of × 400. E The concentration of the serum ANXA2 from RA patients (n = 100) and HCs (n = 100) was determined by ELISA. F The expression of ANXA2 mRNA in synovial tissues and FLSs from RA patients (n = 16) and HCs (n = 16) were detected by qPCR. G, H The expression of ANXA2 in synovial tissues and FLSs from RA patients (n = 16) and HCs (n = 16) were measured by WB. I The expression of the ANXA2 of synovial tissue sections from RA patients and HCs were determined by IHC with a magnification of × 40 and × 200. J Immunofluorescence of CTGF and ANXA2 performed in synovial tissues of RA patients with a magnification of × 200